Chrysos reports record FY26 revenue of $88.1 million as PhotonAssay uptake accelerates
AI Market Summary
Chrysos reported record FY26 revenue and EBITDA, with accelerating global adoption of its PhotonAssay technology and expanding direct-to-mine leases with major gold producers. Strong sample throughput growth and improved margins, alongside refinancing into a larger syndicated facility, signal robust mine-site assay demand and better capacity to scale deployments. While company-specific, the update mildly reinforces strength in gold exploration and production activity.
Impact level
● Low
Affected assets
NCCOGOLD2USD/USDT+1.49%
AI Insight · NCCOGOLD2USD/USDTAI Insight
● Neutral
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
ASX-listed Chrysos Corporation (C79) reported record results for FY26, with revenue, EBITDA and sample throughput all reaching new highs. Total revenue rose 33% to $88.1 million and EBITDA jumped 68% to $27.2 million, both landing at the top end of prior guidance. EBITDA margin improved to 31% from 24%. The company processed a record 11.3 million samples, up 67% year on year, while net operating cash inflow climbed 103% to $17.9 million.
